🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT07295717
Recruiting Phase 1

A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

NCT07295717 · tracked via the Priya Life Science UK tracker
Sponsor
Alnylam Pharmaceuticals
Phase
Phase 1
Started
2025-12-12
Last updated
2026-09-16

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

ALN-4285Placebo

ALN-4285: ALN-4285 will be administered SC

Placebo: Placebo will be administered SC

Study summary

The purpose of this study is to:

* evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers
* characterize the single-dose pharmacokinetics (PK) of ALN-4285

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2 * Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN) * Has total bilirubin \>ULN * Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg * Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening * Has received an investigational agent within the last 30 days or 5 half-lives

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Trial Site London United Kingdom Recruiting

More Alnylam Pharmaceuticals trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07295717 on ClinicalTrials.gov ↗ ← All trials in the UK